<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30765691</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>PLC&#x3b2;2 negatively regulates the inflammatory response to virus infection by inhibiting phosphoinositide-mediated activation of TAK1.</ArticleTitle><Pagination><StartPage>746</StartPage><MedlinePgn>746</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">746</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-08524-3</ELocationID><Abstract><AbstractText>Excessive or uncontrolled release of proinflammatory cytokines caused by severe viral infections often results in host tissue injury or even death. Phospholipase C (PLC)s degrade phosphatidylinositol-4, 5-bisphosphate (PI(4,5)P2) lipids and regulate multiple cellular events. Here, we report that PLC&#x3b2;2 inhibits the virus-induced expression of pro-inflammatory cytokines by interacting with and inhibiting transforming growth factor-&#x3b2;-activated kinase 1 (TAK1) activation. Mechanistically, PI(4,5)P2 lipids directly interact with TAK1 at W241 and N245, and promote its activation. Impairing of PI(4,5)P2's binding affinity or mutation of PIP2-binding sites on TAK1 abolish its activation and the subsequent production of pro-inflammatory cytokines. Moreover, PLC&#x3b2;2-deficient mice exhibit increased expression of proinflammatory cytokines and a higher frequency of death in response to virus infection, while the PLC&#x3b2;2 activator, m-3M3FBS, protects mice from severe Coxsackie virus A 16 (CVA16) infection. Thus, our findings suggest that PLC&#x3b2;2 negatively regulates virus-induced pro-inflammatory responses by inhibiting phosphoinositide-mediated activation of TAK1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yilong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zijuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Basic Medical Sciences &amp; Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, 200032, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Shanghai Jiao Tong University, 200240, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Juehui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Haohao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chunfu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institut Pasteur of Shanghai, 200031, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Juhao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institut Pasteur of Shanghai, 200031, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Qibin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institut Pasteur of Shanghai, 200031, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qingli</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200000, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ajing</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200000, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Lisong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200000, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jinqiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Children's Hospital of Fudan University, 201102, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Dianqing</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Yale School of Medicine, New Haven, CT, 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Caiyun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Institutes of Biomedical Sciences, Fudan University, 200032, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Haojie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Institutes of Biomedical Sciences, Fudan University, 200032, Shanghai, China. luhaojie@fudan.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Dapeng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Basic Medical Sciences &amp; Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, 200032, Shanghai, China. dapengyan@fudan.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Baoxue</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433, Shanghai, China. gebaoxue@sibs.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019269">Phosphatidylinositol 4,5-Diphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.25</RegistryNumber><NameOfSubstance UI="D020930">MAP Kinase Kinase Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.25</RegistryNumber><NameOfSubstance UI="C119860">MAP kinase kinase kinase 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.11</RegistryNumber><NameOfSubstance UI="D054799">Phospholipase C beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020930" MajorTopicYN="N">MAP Kinase Kinase Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019269" MajorTopicYN="N">Phosphatidylinositol 4,5-Diphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054799" MajorTopicYN="N">Phospholipase C beta</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30765691</ArticleId><ArticleId IdType="pmc">PMC6375925</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-08524-3</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-08524-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Jong MD, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 2006;12:1203&#x2013;1207. doi: 10.1038/nm1477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1477</ArticleId><ArticleId IdType="pmc">PMC4333202</ArticleId><ArticleId IdType="pubmed">16964257</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisoncik JR, et al. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 2012;76:16&#x2013;32. doi: 10.1128/MMBR.05015-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.05015-11</ArticleId><ArticleId IdType="pmc">PMC3294426</ArticleId><ArticleId IdType="pubmed">22390970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence. 2014;5:213&#x2013;218. doi: 10.4161/viru.27024.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/viru.27024</ArticleId><ArticleId IdType="pmc">PMC3916377</ArticleId><ArticleId IdType="pubmed">24193365</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IA. The advent of the cytokine storm. Immunol. Cell Biol. 2007;85:271&#x2013;273. doi: 10.1038/sj.icb.7100062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.icb.7100062</ArticleId><ArticleId IdType="pubmed">17551531</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291&#x2013;295. doi: 10.1126/science.1183021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1183021</ArticleId><ArticleId IdType="pmc">PMC3645875</ArticleId><ArticleId IdType="pubmed">20075244</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805&#x2013;820. doi: 10.1016/j.cell.2010.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.022</ArticleId><ArticleId IdType="pubmed">20303872</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 2003;171:4304&#x2013;4310. doi: 10.4049/jimmunol.171.8.4304.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.171.8.4304</ArticleId><ArticleId IdType="pubmed">14530355</ArticleId></ArticleIdList></Reference><Reference><Citation>Meylan E, et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat. Immunol. 2004;5:503&#x2013;507. doi: 10.1038/ni1061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1061</ArticleId><ArticleId IdType="pubmed">15064760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, He C, Wang L, Ge B. Post-translational regulation of antiviral innate signaling. Eur. J. Immunol. 2017;47:1414&#x2013;1426. doi: 10.1002/eji.201746959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201746959</ArticleId><ArticleId IdType="pmc">PMC7163624</ArticleId><ArticleId IdType="pubmed">28744851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001;412:346&#x2013;351. doi: 10.1038/35085597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35085597</ArticleId><ArticleId IdType="pubmed">11460167</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhikari A, Xu M, Chen ZJ. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene. 2007;26:3214&#x2013;3226. doi: 10.1038/sj.onc.1210413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1210413</ArticleId><ArticleId IdType="pubmed">17496917</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya H, et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science. 1996;272:1179&#x2013;1182. doi: 10.1126/science.272.5265.1179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.272.5265.1179</ArticleId><ArticleId IdType="pubmed">8638164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto K, Matsumoto K, Ninomiya-Tsuji J. TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop. J. Biol. Chem. 2000;275:7359&#x2013;7364. doi: 10.1074/jbc.275.10.7359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.10.7359</ArticleId><ArticleId IdType="pubmed">10702308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajino T, et al. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J. Biol. Chem. 2006;281:39891&#x2013;39896. doi: 10.1074/jbc.M608155200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M608155200</ArticleId><ArticleId IdType="pmc">PMC1797071</ArticleId><ArticleId IdType="pubmed">17079228</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiley WW, et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 2007;204:1475&#x2013;1485. doi: 10.1084/jem.20062694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20062694</ArticleId><ArticleId IdType="pmc">PMC2118606</ArticleId><ArticleId IdType="pubmed">17548520</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan YH, et al. USP4 targets TAK1 to downregulate TNFalpha-induced NF-kappaB activation. Cell Death Differ. 2011;18:1547&#x2013;1560. doi: 10.1038/cdd.2011.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2011.11</ArticleId><ArticleId IdType="pmc">PMC3136563</ArticleId><ArticleId IdType="pubmed">21331078</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh PG, et al. Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep. 2008;41:415&#x2013;434. doi: 10.5483/BMBRep.2008.41.6.415.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2008.41.6.415</ArticleId><ArticleId IdType="pubmed">18593525</ArticleId></ArticleIdList></Reference><Reference><Citation>Harden TK, Sondek J. Regulation of phospholipase C isozymes by ras superfamily GTPases. Annu. Rev. Pharmacol. Toxicol. 2006;46:355&#x2013;379. doi: 10.1146/annurev.pharmtox.46.120604.141223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.46.120604.141223</ArticleId><ArticleId IdType="pubmed">16402909</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 2001;70:281&#x2013;312. doi: 10.1146/annurev.biochem.70.1.281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.70.1.281</ArticleId><ArticleId IdType="pmc">PMC4781088</ArticleId><ArticleId IdType="pubmed">11395409</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, et al. Roles of phospholipase C beta2 in chemoattractant-elicited responses. Proc. Natil Acad. Sci. USA. 1997;94:7971&#x2013;7975. doi: 10.1073/pnas.94.15.7971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.15.7971</ArticleId><ArticleId IdType="pmc">PMC21539</ArticleId><ArticleId IdType="pubmed">9223297</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, et al. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science. 2000;287:1046&#x2013;1049. doi: 10.1126/science.287.5455.1046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.287.5455.1046</ArticleId><ArticleId IdType="pubmed">10669417</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg S, Hasko G, Wu D, Leibovich SJ. Suppression of PLCbeta2 by endotoxin plays a role in the adenosine A(2A) receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype. Am. J. Pathol. 2009;175:2439&#x2013;2453. doi: 10.2353/ajpath.2009.090290.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2009.090290</ArticleId><ArticleId IdType="pmc">PMC2789640</ArticleId><ArticleId IdType="pubmed">19850892</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirakawa AK, et al. Pathway-selective suppression of chemokine receptor signaling in B cells by LPS through downregulation of PLC-beta2. Cell. Mol. Immunol. 2010;7:428&#x2013;439. doi: 10.1038/cmi.2010.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2010.46</ArticleId><ArticleId IdType="pmc">PMC3343318</ArticleId><ArticleId IdType="pubmed">20871625</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabol Y, et al. A prospective, comparative study of severe neurological and uncomplicated hand, foot and mouth forms of paediatric enterovirus 71 infections. Int. J. Infect. Dis. 2017;59:69&#x2013;76. doi: 10.1016/j.ijid.2017.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2017.04.005</ArticleId><ArticleId IdType="pubmed">28438677</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox JA, Hiscox JA, Solomon T, Ooi MH, Ng LFP. Immunopathogenesis and virus&#x2013;host interactions of enterovirus 71 in patients with hand, foot and mouth disease. Front. Microbiol. 2017;8:2249. doi: 10.3389/fmicb.2017.02249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.02249</ArticleId><ArticleId IdType="pmc">PMC5713468</ArticleId><ArticleId IdType="pubmed">29238324</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LG, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, Malaysia: clinical and pathological characteristics of the disease. Clin. Infect. Dis. 2000;31:678&#x2013;683. doi: 10.1086/314032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314032</ArticleId><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, et al. Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. Acta Paediatr. 2002;91:632&#x2013;635. doi: 10.1111/j.1651-2227.2002.tb03292.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1651-2227.2002.tb03292.x</ArticleId><ArticleId IdType="pubmed">12162592</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin. Infect. Dis. 2003;36:269&#x2013;274. doi: 10.1086/345905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/345905</ArticleId><ArticleId IdType="pubmed">12539066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J. Clin. Virol. 2006;37:47&#x2013;52. doi: 10.1016/j.jcv.2006.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2006.05.009</ArticleId><ArticleId IdType="pubmed">16861032</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Foo DG, Trasti SL, Tan EL, Alonso S. Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J. Virol. 2011;85:3067&#x2013;3076. doi: 10.1128/JVI.01779-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01779-10</ArticleId><ArticleId IdType="pmc">PMC3067852</ArticleId><ArticleId IdType="pubmed">21228224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajibade AA, Wang HY, Wang RF. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol. 2013;34:307&#x2013;316. doi: 10.1016/j.it.2013.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2013.03.007</ArticleId><ArticleId IdType="pubmed">23664135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks SN, et al. General and versatile autoinhibition of PLC isozymes. Mol. Cell. 2008;31:383&#x2013;394. doi: 10.1016/j.molcel.2008.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2008.06.018</ArticleId><ArticleId IdType="pmc">PMC2702322</ArticleId><ArticleId IdType="pubmed">18691970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Liu CC. Cytokine immunopathogenesis of enterovirus 71 brain stem encephalitis. Clin. Dev. Immunol. 2012;2012:876241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3432373</ArticleId><ArticleId IdType="pubmed">22956971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae YS, et al. Identification of a compound that directly stimulates phospholipase C activity. Mol. Pharmacol. 2003;63:1043&#x2013;1050. doi: 10.1124/mol.63.5.1043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.63.5.1043</ArticleId><ArticleId IdType="pubmed">12695532</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim JH, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005;19:2668&#x2013;2681. doi: 10.1101/gad.1360605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1360605</ArticleId><ArticleId IdType="pmc">PMC1283960</ArticleId><ArticleId IdType="pubmed">16260493</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogensen TH, Melchjorsen J, Hollsberg P, Paludan SR. Activation of NF-kappa B in virus-infected macrophages is dependent on mitochondrial oxidative stress and intracellular calcium: downstream involvement of the kinases TGF-beta-activated kinase 1, mitogen-activated kinase/extracellular signal-regulated kinase kinase 1, and I kappa B kinase. J. Immunol. 2003;170:6224&#x2013;6233. doi: 10.4049/jimmunol.170.12.6224.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.12.6224</ArticleId><ArticleId IdType="pubmed">12794154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikkelsen SS, et al. RIG-I-mediated activation of p38 MAPK is essential for viral induction of interferon and activation of dendritic cells: dependence on TRAF2 and TAK1. J. Biol. Chem. 2009;284:10774&#x2013;10782. doi: 10.1074/jbc.M807272200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M807272200</ArticleId><ArticleId IdType="pmc">PMC2667765</ArticleId><ArticleId IdType="pubmed">19224920</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey N, Liu T, Garofalo RP, Casola A. TAK1 regulates NF-KappaB and AP-1 activation in airway epithelial cells following RSV infection. Virology. 2011;418:93&#x2013;101. doi: 10.1016/j.virol.2011.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.07.007</ArticleId><ArticleId IdType="pmc">PMC3164748</ArticleId><ArticleId IdType="pubmed">21835421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, et al. Enhanced phosphatidylinositol 4-phosphate 5-kinase alpha expression and PI(4,5)P2 production in LPS-stimulated microglia. Neurochem. Int. 2010;57:600&#x2013;607. doi: 10.1016/j.neuint.2010.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2010.07.008</ArticleId><ArticleId IdType="pubmed">20659513</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TT, et al. Phosphatidylinositol 4-phosphate 5-kinase alpha facilitates Toll-like receptor 4-mediated microglial inflammation through regulation of the Toll/interleukin-1 receptor domain-containing adaptor protein (TIRAP) location. J. Biol. Chem. 2013;288:5645&#x2013;5659. doi: 10.1074/jbc.M112.410126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.410126</ArticleId><ArticleId IdType="pmc">PMC3581370</ArticleId><ArticleId IdType="pubmed">23297396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell. 2006;125:943&#x2013;955. doi: 10.1016/j.cell.2006.03.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.03.047</ArticleId><ArticleId IdType="pubmed">16751103</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z, et al. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J. Biol. Chem. 2003;278:16713&#x2013;16719. doi: 10.1074/jbc.M300562200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M300562200</ArticleId><ArticleId IdType="pubmed">12609980</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc. Natl Acad. Sci. USA. 2004;101:3533&#x2013;3538. doi: 10.1073/pnas.0308496101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0308496101</ArticleId><ArticleId IdType="pmc">PMC373497</ArticleId><ArticleId IdType="pubmed">14982987</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasai M, et al. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway. Mol. Immunol. 2010;47:1283&#x2013;1291. doi: 10.1016/j.molimm.2009.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2009.12.002</ArticleId><ArticleId IdType="pubmed">20047764</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CK, et al. Pathogenicity of the novel A/H7N9 influenza virus in mice. mBio. 2013;4:16. doi: 10.1128/mBio.00362-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00362-13</ArticleId><ArticleId IdType="pmc">PMC3705449</ArticleId><ArticleId IdType="pubmed">23820393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, et al. The kinase CK1varepsilon controls the antiviral immune response by phosphorylating the signaling adaptor TRAF3. Nat. Immunol. 2016;17:397&#x2013;405. doi: 10.1038/ni.3395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3395</ArticleId><ArticleId IdType="pubmed">26928339</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>